Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

6.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.5K
Upstream Processing01:27

Upstream Processing

85
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
85
Drug Discovery: Overview01:26

Drug Discovery: Overview

13.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
13.4K
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

67
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
67
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

5.1K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
5.1K
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

285
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
285

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional characterisation of Target of Rapamycin (TOR) signalling in Physcomitrella.

Plant cell reports·2026
Same author

Secretion-based production of prolyl-hydroxylated human type III collagen in scalable Physcomitrella photobioreactors.

Plant cell reports·2026
Same author

CRISPR/Cas9 targeted genetic screening in Physcomitrella identifies novel cell division genes.

Frontiers in plant science·2025
Same author

Production of human papillomavirus type 16 virus-like particles in Physcomitrella photobioreactors.

Plant cell reports·2025
Same author

Multiplication of peat moss (Sphagnum L.) species for climate action.

Journal of experimental botany·2025
Same author

Thrombospondin-1 inhibits alternative complement pathway activation in antineutrophil cytoplasmic antibody-associated vasculitis.

The Journal of clinical investigation·2025

Related Experiment Video

Updated: Apr 11, 2026

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.5K

Moss-made pharmaceuticals: from bench to bedside.

Ralf Reski1,2,3, Juliana Parsons1, Eva L Decker1

  • 1Plant Biotechnology, Faculty of Biology, University of Freiburg, Freiburg, Germany.

Plant Biotechnology Journal
|May 27, 2015
PubMed
Summary
This summary is machine-generated.

The moss Physcomitrella patens is a powerful system for producing biopharmaceuticals, including therapeutic proteins and antibodies. This model organism offers high-quality, stable production, with a drug for Fabry disease in clinical trials.

Keywords:
ADCCMorbus FabryPhyscomitrella patensbiobetterknockout mossmoss bioreactor

More Related Videos

A Customizable Approach for the Enzymatic Production and Purification of Diterpenoid Natural Products
07:59

A Customizable Approach for the Enzymatic Production and Purification of Diterpenoid Natural Products

Published on: October 4, 2019

10.5K
Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome
09:06

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome

Published on: December 12, 2025

898

Related Experiment Videos

Last Updated: Apr 11, 2026

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.5K
A Customizable Approach for the Enzymatic Production and Purification of Diterpenoid Natural Products
07:59

A Customizable Approach for the Enzymatic Production and Purification of Diterpenoid Natural Products

Published on: October 4, 2019

10.5K
Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome
09:06

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome

Published on: December 12, 2025

898

Area of Science:

  • Plant biotechnology
  • Biopharmaceutical production
  • Moss-based expression systems

Background:

  • The moss Physcomitrella patens has emerged as a significant model organism over the past two decades.
  • It is utilized in both fundamental research and biotechnological applications.

Purpose of the Study:

  • To highlight the capabilities of Physcomitrella patens as a platform for producing recombinant biopharmaceuticals.
  • To showcase the advantages of moss-based systems over traditional methods.

Main Methods:

  • Utilizing Physcomitrella patens for precise genome engineering via homologous recombination.
  • Implementing Good Manufacturing Practice (GMP) compliant production in moss bioreactors.
  • Upscaling production to 500 L wave reactors.

Main Results:

  • Demonstrated excellent homogeneity of protein glycosylation and remarkable batch-to-batch stability.
  • Successfully produced various human proteins, including monoclonal antibodies (e.g., enhanced ADCC), VEGF, FH, FGF7/KGF, EGF, HGF, asialo-EPO, alpha-galactosidase, and beta-glucocerebrosidase.
  • Developed an Env-derived multi-epitope HIV protein candidate vaccine.
  • Achieved superior quality recombinant proteins compared to mammalian systems (e.g., CHO cells), termed 'biobetters'.
  • Initiated metabolic engineering efforts in P. patens.

Conclusions:

  • Physcomitrella patens offers a robust and scalable platform for biopharmaceutical manufacturing.
  • Moss-derived biopharmaceuticals can achieve high quality and stability, with potential for improved therapeutic efficacy.
  • The system is validated for clinical applications, as evidenced by alpha-galactosidase for Fabry disease entering clinical trials.